Monobody

Mono bodysuits, also called Adnectine are artificial proteins which are capable of binding antigens. Although its name suggests a relationship to antibodies (English antibody ), they are structurally not derived from immunoglobulins, but from fibronectin. Monobodies consist of 94 amino acids and are about 15 times smaller than antibodies of the IgG type with a molecular mass of about 10 kDa. Monobodies be the major contributor for the since 2007 to Bristol -Myers Squibb belonging biotech companies Adnexus. The monobody Pegdinetanib (CT -322, Angiocept ), a VEGF receptor antagonist, is currently in the second phase of clinical development for the treatment of glioblastoma and other cancers.

Structure

Monobodies are from human fibronectin, more precisely, derived from the tenth extracellular fibronectin domain of type III. This domain has an immunoglobulin-like β -sheet structure with 3 -exposed loops per side. Modifications in the loops BC and FG of the Fibronectindomänen lead to monobodies with different protein recognition patterns. In the structure of monobodies metal ion binding sites and the central disulfide bridge missing.